Insulin Resistance Intervention after Stroke (IRIS) Trial
Related Clinical Trials
Antihypertensive Treatment of Acute Cerebral Hemorrhage-II (ATACH-II)
An intracerebral hemorrhage (ICH) is a hemorrhagic stroke that is caused by bleeding from a blood vessel in the brain. Intracerebral hemorrhages have a high risk of death and disability and expansion of the hemorrhage is predictive of a poorer outcome. The purpose of this study is to find out if there is a benefit to reducing systolic blood pressure (SBP) in a more intensive way (keeping SBP less than 140 mmHg) compared with standard SBP treatment (keeping SBP less than 180 mmHg). This study uses an FDA approved drug called nicardipine to reduce the blood pressure after ICH. Reducing blood pressure in the early stages of ICH is thought to limit the amount of brain damage that occurs. Less brain damage may reduce the high levels of death and disability commonly found in this form of stroke. The primary way the study team will measure if intensive SBP treatment is better than standard SBP treatment is by following the patient’s stroke recovery for 90 days.
Controlled trial to evaluate the safety and efficacy of the Starflex Septal Closure System
CLOSURE I: Prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the Starflex Septal Closure System vs. best medical therapy in patients with a stroke and/or transient ischemic attack due to presumed paradoxical embolism through a patient foramen ovale To compare the STARFlex device and medication group to the medication-alone group in preventing a recurrent stroke or TIA associated with a PFO. Study conducted in up to 120 centers across the U.S. involving about 800 patients – those with stroke or definite clinical TIA within 6 months, without other definable cause.
WARCEF - Warfarn vs. Aspirin in Reduced Cardiac Ejection Fraction
WARCEF - Warfarn vs. Aspirin in Reduced Cardiac Ejection Fraction. Includes Change in Eligibility Criteria (Eligibility Ejection Fraction Has Been Increased From less than 30 to less than 35%) To compare the efficacy and safety of Warfarin (INR 2.0-3.0) with aspirin (325 mg per day) for preventing all-cause mortality and disability in patients with cardiac EF less than 35%.